Stock SMMT SUMMIT THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Delayed Nasdaq
Other stock markets
 03:58:53 2024-05-21 pm EDT 		5-day change 1st Jan Change
4.385 USD -3.41% Intraday chart for Summit Therapeutics Inc. -6.30% +68.20%
May. 07 Citigroup Starts Summit Therapeutics With Buy Rating, $7 Price Target MT
May. 01 Transcript : Summit Therapeutics Inc., Q1 2024 Earnings Call, May 01, 2024

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Citigroup Starts Summit Therapeutics With Buy Rating, $7 Price Target
MT
Transcript : Summit Therapeutics Inc., Q1 2024 Earnings Call, May 01, 2024
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
BU
Summit Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
BU
Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
BU
Summit Therapeutics Inc. Appoints Dr. Mostafa Ronaghi to Its Board of Directors
CI
Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
BU
Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed
RE
Illumina Names Ankur Dhingra as Chief Financial Officer
MT
Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor
RE
Summit Therapeutics Appoints COO to Additional Role of CFO
MT
Summit Therapeutics Inc. Announces Chief Financial Officer Changes
CI
Summit Therapeutics Inc. Appoints Bhaskar Anand as Chief Accounting Officer, Head of Finance, to Serve as Its Principal Accounting Officer
CI
Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans
MT
Summit Therapeutics Insider Bought Shares Worth $375,000, According to a Recent SEC Filing
MT
Stifel Initiates Summit Therapeutics With Buy Rating, $8 Price Target
MT
Summit Therapeutics Inc. - Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
AQ
Summit Therapeutics Reports 23% Complete Response in Metastatic NSCL Cancer Drug Ivonescimab's Clinical Trials
MT
Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SMMT Stock
  4. News Summit Therapeutics Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW